Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials That Incorporate Multiple Genetic and Biomarker Research Results

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2020 Dec 18

PMID 33337371

Citations 12

Authors

Jessica Mozersky

Sarah Hartz

Erin Linnenbringer

Lillie Levin

Marissa Streitz

Kristin Stock

Krista Moulder

John C Morris

Affiliations

Soon will be listed here.

Abstract

Background: Cognitively normal (CN) older adults participating in Alzheimer's disease (AD) research increasingly ask for their research results-including genetic and neuroimaging findings-to understand their risk of developing AD dementia. AD research results are typically not returned for multiple reasons, including possible psychosocial harms of knowing one is at risk of a highly feared and untreatable disease.

Objective: We developed materials that convey information about 5-year absolute risk of developing AD dementia based on research results.

Methods: 20 CN older adults who received a research brain MRI result were interviewed regarding their wishes for research results to inform material development (Pilot 1). Following material development, 17 CN older adults evaluated the materials for clarity and acceptability (Pilot 2). All participants were community-dwelling older adults participating in longitudinal studies of aging at a single site.

Results: Participants want information on their risk of developing AD dementia to better understand their own health, satisfy curiosity, inform family, and future planning. Some articulated concerns, but the majority wanted to know their risk despite the limitations of information. Participants found the educational materials and results report clear and acceptable, and the majority would want to know their research results after reviewing them.

Conclusion: These materials will be used in a clinical study examining the psychosocial and cognitive effects of offering research results to a cohort of CN older adults. Future AD research may incorporate the return of complex risk information to CN older adults, and materials are needed to communicate this information.

Citing Articles

Ethical issues in genomics research in persons with Alzheimer's Disease/Alzheimer's Disease-related dementia (AD/ADRD): a systematic review.

Yakubu A, Adedeji I, Maduka O, Jegede A, Adebamowo C BMC Med Ethics. 2024; 25(1):138.

PMID: 39587628 PMC: 11587778. DOI: 10.1186/s12910-024-01141-w.

Double-Edged Sword: A Positive Brain Scan Result Heightens Confidence in an Alzheimer's Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette-Based Experiment.

Stites S, Lee B, Largent E, Harkins K, Sankar P, Krieger A J Gerontol B Psychol Sci Soc Sci. 2024; 79(8).

PMID: 38869988 PMC: 11237985. DOI: 10.1093/geronb/gbae109.

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective.

Patel K, Yang D, Feldman H, Hsiung G, Nygaard H, Best J Alzheimers Dement (N Y). 2024; 10(2):e12463.

PMID: 38596482 PMC: 10999946. DOI: 10.1002/trc2.12463.

The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility.

Robillard J, Masellis M, Martin S, Khachaturian A, Dixon R J Alzheimers Dis. 2024; 97(3):1083-1090.

PMID: 38306053 PMC: 10836546. DOI: 10.3233/JAD-230359.

Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.

Smith H, Robinson J, Levchenko A, Pereira S, Pascual B, Bradbury K J Alzheimers Dis. 2024; 97(3):1261-1274.

PMID: 38250770 PMC: 10894569. DOI: 10.3233/JAD-230609.

References

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

Mayeda E, Glymour M, Quesenberry C, Whitmer R . Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016; 12(3):216-24. PMC: 4969071. DOI: 10.1016/j.jalz.2015.12.007. View

Langlois C, Bradbury A, Wood E, Roberts J, Kim S, Riviere M . Alzheimer's Prevention Initiative Generation Program: Development of an genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2020; 5:705-716. PMC: 6944715. DOI: 10.1016/j.trci.2019.09.013. View

Ravitsky V, Wilfond B . Disclosing individual genetic results to research participants. Am J Bioeth. 2006; 6(6):8-17. DOI: 10.1080/15265160600934772. View

Caselli R, Langbaum J, Marchant G, Lindor R, Hunt K, Henslin B . Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014; 89(10):1389-96. PMC: 4369785. DOI: 10.1016/j.mayocp.2014.05.016. View

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

Willis A, Smith S, Meiser B, Ballinger M, Thomas D, Young M . Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review. Clin Genet. 2016; 92(2):121-133. DOI: 10.1111/cge.12868. View

Gilmore-Bykovskyi A, Jin Y, Gleason C, Flowers-Benton S, Block L, Dilworth-Anderson P . Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review. Alzheimers Dement (N Y). 2020; 5:751-770. PMC: 6944728. DOI: 10.1016/j.trci.2019.09.018. View

10.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

11.

Barthelemy N, Horie K, Sato C, Bateman R . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020; 217(11). PMC: 7596823. DOI: 10.1084/jem.20200861. View

12.

Schnieders T, Danner D, McGuire C, Reynolds F, Abner E . Incentives and barriers to research participation and brain donation among African Americans. Am J Alzheimers Dis Other Demen. 2013; 28(5):485-90. PMC: 3740062. DOI: 10.1177/1533317513488922. View

13.

Burns J, Johnson D, Liebmann E, Bothwell R, Morris J, Vidoni E . Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017; 13(9):1024-1030. PMC: 5582024. DOI: 10.1016/j.jalz.2017.01.022. View

14.

Lingler J, Butters M, Gentry A, Hu L, Hunsaker A, Klunk W . Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. J Alzheimers Dis. 2016; 52(1):17-24. PMC: 4860948. DOI: 10.3233/JAD-150985. View

15.

Wikler E, Blendon R, Benson J . Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther. 2013; 5(5):43. PMC: 3978817. DOI: 10.1186/alzrt206. View

16.

Palmqvist S, Janelidze S, Quiroz Y, Zetterberg H, Lopera F, Stomrud E . Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020; 324(8):772-781. PMC: 7388060. DOI: 10.1001/jama.2020.12134. View

17.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

18.

Gooblar J, Roe C, Selsor N, Gabel M, Morris J . Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. JAMA Neurol. 2015; 72(12):1484-90. PMC: 4694568. DOI: 10.1001/jamaneurol.2015.2875. View

19.

Otado J, Kwagyan J, Edwards D, Ukaegbu A, Rockcliffe F, Osafo N . Culturally Competent Strategies for Recruitment and Retention of African American Populations into Clinical Trials. Clin Transl Sci. 2015; 8(5):460-6. PMC: 4626379. DOI: 10.1111/cts.12285. View

20.

Smedinga M, Tromp K, Schermer M, Richard E . Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion. J Alzheimers Dis. 2018; 66(4):1309-1322. DOI: 10.3233/JAD-180638. View